文献速递肝胆胰外科胃肠外科

二期肝切除与肝移植治疗临界可切除广泛双叶结直肠癌肝转移的比较

Two-stage Hepatectomy Versus Liver Transplantation for Patients With Marginally Resectable Extensive Bilobar Colorectal Liver Metastases.
PubMed 文献 · Ann Surg · 2025-08-12

本研究单中心回顾性比较2016至2023年32例因广泛双叶结直肠癌肝转移行二期肝切除(TSH)与19例因不可切除肝转移行肝移植(LT)的患者,发现LT组总生存、无复发生存及手术失败时间均显著优于TSH组,倾向性评分匹配后结果一致。

要点

  • LT组5年OS为84%,TSH组为32%,差异显著(P=0.003)。
  • LT组5年RFS为24%,TSH组为0%(P=0.0001)。
  • 多因素分析中LT是OS的独立预后因素(HR=0.20,P=0.01)。

核心结论

  • 对于广泛双叶但可切除的肝脏局限结直肠癌肝转移,肝移植可能比二期肝切除获得更好的肿瘤学结局。

研究设计与样本

  • 单中心回顾性比较研究,纳入2016至2023年行二期肝切除的广泛双叶结直肠癌肝转移患者32例(切除组)和行肝移植的不可切除肝脏局限结直肠癌肝转移患者19例(移植组)。
  • 采用意向性治疗和符合方案两种方式分析,并使用倾向性评分匹配提高组间可比性。

主要发现

  • 移植组总生存、无复发生存和手术失败时间均显著优于切除组(5年OS:84% vs 32%,P=0.003;5年RFS:24% vs 0%,P=0.0001;5年TSF:61% vs 7.7%,P<0.0001)。
  • 多因素分析显示左侧原发肿瘤(HR=0.38,P=0.049)和肝移植(HR=0.20,P=0.01)是OS的独立有利预后因素。
  • 倾向性评分匹配后上述结果得到确认。

临床怎么用

  • 在筛选广泛双叶但可切除的肝脏局限结直肠癌肝转移患者时,肝移植可作为二期肝切除之外的潜在替代方案进行个体化评估。

局限性

  • 研究为单中心回顾性设计,样本量较小(切除组32例,移植组19例),组间不可切除性和病灶数目存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare outcomes after two-stage hepatectomy (TSH) or liver transplantation (LT) in patients with extensive bilobar colorectal liver metastases (CRLM). BACKGROUND: Given the high rate of intrahepatic recurrence after TSH in patients with resectable but extensive bilobar CRLM, LT may be an alternative option. However, studies comparing TSH for potentially resectable patients to LT for unresectable ones are lacking. METHODS: We compared oncological outcomes of consecutive patients who underwent TSH for extensive bilobar CRLM (resection group, n=32) without extrahepatic disease with those of all patients who underwent LT for unresectable liver-only CRLM (LT group, n=19) at a single center within the 2016 to 2023 period. Results were analysed both in intention to treat and in per protocol. Propensity score matching (PSM) was used to refine the comparability of both groups. RESULTS: The baseline and biological tumor characteristic of both groups were comparable except for unresectability and higher number of lesions in the LT group. Overall survival (OS), recurrence-free survival (RFS), and time to surgical failure (TSF) in the LT group were all significantly better than those in the TSH group (5-year OS: 84% vs 32%, P =0.003, 5-year RFS: 24% vs 0%, P =0.0001, 5-year TSF: 61% vs 7.7%, P <0.0001). Multivariable analysis revealed that left primary sidedness [hazard ratio (HR): 0.38, P =0.049] and LT (HR: 0.20, P =0.01) were independent prognostic factors of favorable OS. These results were confirmed after PSM. CONCLUSIONS: Our results suggest that LT might achieve better outcomes than TSH in patients with extensive bilobar but resectable liver-only CRLM.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Nakao Y, Adam R, Nasser AH, et al. Two-stage Hepatectomy Versus Liver Transplantation for Patients With Marginally Resectable Extensive Bilobar Colorectal Liver Metastases. Ann Surg. 2025. PMID: 40795061. doi:10.1097/SLA.0000000000006904

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。